Abstract
An enzyme-responsive, paclitaxel-loaded nanoparticle is described and assessed in vivo in a human fibrosarcoma murine xenograft. This work represents a proof-of-concept study demonstrating the utility of enzyme-responsive nanoscale drug carriers capable of targeted accumulation and retention in tumor tissue in response to overexpressed endogenous enzymes.
Keywords:
drug delivery; enzyme-responsive; nanomaterials; self-assembly; stimuli-responsive.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents, Phytogenic / administration & dosage*
-
Cell Line, Tumor
-
Cohort Studies
-
Drug Carriers* / chemistry
-
Drug Evaluation, Preclinical
-
Fibrosarcoma / drug therapy*
-
Fibrosarcoma / enzymology
-
Fluorescence Resonance Energy Transfer
-
Humans
-
Matrix Metalloproteinases / metabolism*
-
Maximum Tolerated Dose
-
Mice, Nude
-
Micelles
-
Microscopy, Electron, Transmission
-
Nanoparticles* / chemistry
-
Neoplasm Transplantation
-
Optical Imaging
-
Paclitaxel / administration & dosage*
-
Polymers / chemistry
-
Tumor Burden
Substances
-
Antineoplastic Agents, Phytogenic
-
Drug Carriers
-
Micelles
-
Polymers
-
Matrix Metalloproteinases
-
Paclitaxel